"The FDA approval of Provenge leads to a huge spike for biotech firm."
http://www.forbes.com/2010/04/29/dendreon-provenge-fda-markets-equities-biotechnology.html?boxes=Homepagechannels
Also explains the halt in DNDN.
If VHL gets good phase II results from the VIR-201 trial it's gonna fly! Therapeutic vaccines just received an absolutely HUGE vote of confidence from the biggest player in the industry... the FDA.
I hope Virax management are following the story, and leverage via an investor roadshow or the like.
Victory smells close!
Add to My Watchlist
What is My Watchlist?
